Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.54 |
| ▸ | PDE11A | Q9HCR9 | 11/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152336 | 1.00 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL16393759 | 1.00 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL16393762 | 1.00 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL12464378 | 0.95 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL12705552 | 0.92 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL12396146 | 0.92 | PDE4B (0.53) | PDE4BPDE11APDE10A | |
| SCHEMBL13919447 | 0.92 | PDE4B (0.53) | PDE4BPDE11APDE10A | |
| SCHEMBL12170411 | 0.89 | PDE4B (0.51) | PDE4BPDE11APDE10A | |
| SCHEMBL13919907 | 0.88 | PDE4B (0.59) | PDE4BPDE11APDE10A | |
| SCHEMBL691228 | 0.88 | PDE4B (0.58) | PDE4BPDE11APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484382-A1 | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form | Schering Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| US-20100263665-A1 | DOSE COUNTER MECHANISM | MERCK SHARP & DOHME CORP. | 2010-10-21 | — | — | US | claimed |
| US-20100083964-A1 | DISPENSER DOSE COUNTER MECHANISM | SCHERING CORPORATION | 2010-04-08 | — | — | US | claimed |
| US-20090298802-A1 | Pharmaceutical Compositions | MERCK SHARP & DOHME CORP. | 2009-12-03 | — | — | US | claimed |
| EP-2099514-A2 | DOSE COUNTER MECHANISM | SCHERING CORPORATION (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008079350-A2 | DOSE COUNTER MECHANISM | SCHERING CORPORATION (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1879620-A2 | MEDICAMENTS AND METHODS COMBINING AN ANTICHOLINERGIC, A CORTICOSTEROID, AND A LONG ACTING BETA AGONIST | SCHERING CORPORATION (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006105401-A2 | MEDICAMENTS AND METHODS COMBINING AN ANTICHOLINERGIC, A CORTICOSTEROID, AND A LONG ACTING BETA AGONIST | SCHERING CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| EP-3082708-B1 | MEDIA MILLING PROCESS FOR THE MANUFACTURE OF ACTIVE PHARMACEUTICAL INGREDIENTS IN PROPELLANTS | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20160317391-A1 | MEDIA MILLING PROCESS FOR THE MANUFACTURE OF ACTIVE PHARMACEUTICAL INGREDIENTS IN PROPELLANTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9174012-B2 | Drug products, dry powder inhalers and polyflux collider arrangements | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130000639-A1 | DRUG PRODUCTS, DRY POWDER INHALERS AND POLYFLUX COLLIDER ARRANGEMENTS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| US-20120304991-A1 | DRUG PRODUCTS AND DRY POWDER INHALERS WITH MULTIPLE RESERVOIRS | MERCK SHARP & DOHME CORP. | 2012-12-06 | — | — | US | disclosed |
| EP-2484382-A1 | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form | Schering Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20080253970-A1 | Stable Pharmaceutical Drug Products | SCHERING CORPORATION | 2008-10-16 | — | — | US | disclosed |
| WO-2008097233-A1 | STABLE PHARMACEUTICAL DRUG AEROSOLS | SCHERING CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| EP-1879620-A2 | MEDICAMENTS AND METHODS COMBINING AN ANTICHOLINERGIC, A CORTICOSTEROID, AND A LONG ACTING BETA AGONIST | SCHERING CORPORATION (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008008327-A2 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006105401-A2 | MEDICAMENTS AND METHODS COMBINING AN ANTICHOLINERGIC, A CORTICOSTEROID, AND A LONG ACTING BETA AGONIST | SCHERING CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | XDH, UPF1, NOX5 | PDE4B 461/4885PDE11A 1277/4885PDE10A 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.